Introduction
Breast cancer is a highly heterogeneous disease and the need for individualized therapy is widely accepted. In addition to clinical parameters such as tumor size and grade, lymph node involvement and patient demographics, several molecular markers are employed in routine patient care [1] [2] [3] . The most important ones include the estrogen receptor (ER), the progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2). ERpositive tumors are thought to have characteristics of the luminal cell type and are frequently responsive to endocrine treatment (such as tamoxifen or aromatase inhibitors) [4, 5] . ER-negative tumors are considered to be more similar to the basal cell type and do not respond to endocrine treatment. Tumors with a HER2 gene amplification may respond to targeted therapy, such as trastuzumab or lapatinib [6] [7] [8] . The PR is a prognostic marker, but the Oxford overview of adjuvant therapy does not support its ability to predict resistance to chemotherapy (CT). It is sometimes stated that ER? IHC /PR? IHC tumors coincide with the Luminal A mRNA breast cancer subtype [9] .
The most standardized way of assessing the status of these biomarkers is immunohistochemistry (IHC). Using antibodies with specificity for each marker, the number of positively staining cells can be estimated by the pathologist from a section of the tumor. Although widely accepted and available, the technique is not perfect. The determination of HER2 protein expression status based on IHC is known to have a false-positive rate around 10%, even in experienced laboratories [10, 11] . Many institutions also perform fluorescent or chromogenic in situ hybridization (FISH or CISH) to confirm HER2 gene amplification or to establish its presence or absence when IHC results are ambiguous. Since the choice of treatment critically depends on the HER2 gene amplification status, highly reliable analyses are essential [12] . Subtyping of breast cancer by IHC assays for ER, PR and IHC and in situ hybridization for HER2, yields three broad groups: Luminal IHC , when ER is positive and HER2 is not amplified; HER2? IHC tumors, which may be ER? or ER-; and triple negative tumors (TN IHC ) when ER, PR and HER2 are all negative [13, 14] .
More recently, an mRNA expression-based subtyping of breast cancer, introduced by Perou et al. [15] has gained wide acceptance. These investigators identified an intrinsic gene set that distinguished five different molecular subtypes: Luminal A mRNA , Luminal B mRNA , HER2? mRNA , Basal mRNA and Normal-like mRNA [15] [16] [17] . Several studies have shown that the Luminal A mRNA subtype is associated with a favorable prognosis, while the Basal mRNA subtype is prognostically unfavorable [16] [17] [18] . This raises the question of how well the two subtyping systems match and whether the molecular subtyping adds predictive power to the IHC subtyping in the neoadjuvant setting. To our knowledge, no such formal analysis has been performed. In this paper, we present the results of a comparative analysis on 195 patients.
Patients and methods

Patients
Biopsies of primary breast tumors were collected from 195 women who received neoadjuvant treatment at the Netherlands Cancer Institute between 2000 and 2007. These patients took part in one of two ongoing clinical trials or received standard treatment. All patients eligible for preoperative chemotherapy were diagnosed with invasive breast cancer and either a tumor diameter of at least 3 cm, lymph node involvement or both. Both trials were approved by the ethical committee and informed consent was obtained from all patients. Biopsies were taken using a core needle under ultrasound guidance. After collection, specimens were snap-frozen in liquid nitrogen and stored at -70°C.
Neoadjuvant chemotherapy for Luminal IHC and TN IHC tumors consisted of either dose-dense AC (doxorubicin and cyclophosphamide, standard arm) or docetaxel and capecitabine (experimental arm) for three courses. After evaluation, by comparing a repeat contrast-enhanced MRI to a prechemotherapy MRI, patients with favorably responding tumors continued their initial chemotherapy and patients with minimal response or stable disease were switched to the alternative chemotherapy regimen [19] . Most tumors harboring HER2 gene amplifications were treated with trastuzumab and weekly paclitaxel and carboplatin (37 of 43 tumors). The other six patients with HER2? tumors, who started treatment before 2006, began treatment with dose-dense AC. Details of the studies will be published separately. For four patients, no response data were available and as a result the therapy response analysis was limited to 191 patients. An overview of patient and tumor characteristics is given in Table 1 .
Response evaluation
The response to treatment at the time of surgery was taken as an end point. Both pathology and MRI findings were used for response evaluation. We included both the response of the primary tumor and the nodal status after treatment in our definition of pathological response.
Only patients with a complete absence of invasive tumor cells (irrespective of carcinoma in situ) in the surgical specimen of the breast (i.e., pCR of the primary tumor) and of the lymph nodes were considered to have a pCR. It has been shown that pCR correlates with outcome and that patients achieving a pCR by this definition have a very good prognosis [20] [21] [22] [23] [24] [25] . The response of the primary tumor was categorized in additional categories as described in the following paragraphs.
When only a small number of scattered tumor cells were present at pathology examination, the response was classified as a 'near pCR' (npCR). Patients with primary tumor shrinkage of more than 50% but with residual tumor were considered partial responders (PR). And at last, patients with tumor shrinkage of less than 50% as evaluated by MRI and pathological assessment were considered to be non-responders (NR). The MRIs were performed and interpreted as reported previously [19] .
Immunohistochemistry
Paraffin-embedded sections were immunohistochemically assessed as described previously with the following exceptions [26] . ER and PR positivity was defined as at least 10% of cells staining positive for ER or PR, respectively. The IHC staining for HER2 was scored according to standard criteria as 0, 1?, 2? or 3?. Scores of 0 and 1? were considered negative and 3? was considered positive. When a score of 2? was found, additional CISH testing was done to establish HER2 gene amplification status. CISH testing was also done when the IHC score was 3? but no high HER2 expression was encountered in the mRNA expression microarray analysis. Tumors with at least five HER2 copies per nucleus, as detected by CISH, were considered HER2?. The tumor grade was assessed using the Elston and Ellis method [27].
Molecular subtyping mRNA isolation and extraction from the frozen material were performed as described previously [26] . A 5-lm section halfway through the biopsy was stained for hematoxylin and eosin and analyzed by a pathologist for tumor percentage. Only samples that contained at least 50% tumor cells were subsequently analyzed on a microarray. The microarray analysis was performed as described previously, except no filtering of genes was done [26] . Briefly, all samples were hybridized in dye-swap to in-house printed 35 k Operon microarrays using a reference pool of 100 invasive breast carcinomas. Background-corrected intensities were used to calculate log 2 transformed ratios and the ratios were normalized using a lowess fit per subarray.
The subtype single sample predictor developed by Hu et al. [18. ] was used to assign a molecular subtype to the samples based on their expression profiles across the intrinsic gene set. Briefly, we mapped the intrinsic genes to the Operon platform (Supplemental data file 1), when a single gene was represented by multiple probes the average of the corresponding probes was used. Subsequently, for all samples the Spearman correlation of a sample to the centroid of each corresponding molecular subtype was calculated. Each sample was then assigned to the subtype with the highest correlation coefficient.
Endocrine responsiveness
The endocrine responsiveness index (ERI) was defined as was described by Colleoni et al. [28] . Tumors were classified as highly endocrine responsive when ER and PR were positive in at least 50% of the cells, as incompletely endocrine responsive when either ER or PR was positive in less than 50% of the cells and as endocrine non-responsive when both ER and PR were negative in all cells.
Statistical tests
Concordance between IHC and molecular subtyping was assessed by the percentage of concordance and by the kappa test [29] . The Fisher exact test was used to assess the association between the different subtype groupings and the treatment response in terms of pCR. For the univariate and multivariate analyses, logistic regression was employed. The Cochran-Armitage exact test was used to determine trend effects. The Mann-Whitney test was used to assess PTEN mRNA expression differences between groups. All data analyses were performed using the R software package.
Results
Concordance of clinical and molecular subtypes
To assess the concordance of the subtypes, we (1) (Table 5) resulting in a slightly (and not significantly) higher pCR rate in the Luminal B mRNA subgroup (P = 0.44, Fisher exact test).
Response rates of the primary tumor
The effect of treatment on the breast tumor alone is shown in Table 6 , 7. In this overview, the Luminal groups again show a worse response than the non-Luminal groups, although more than half of the Luminal tumors are being classified as partial responders.
Discussion
The relevance of molecular subtyping for breast cancer has achieved widespread acceptance. Both the clinical and the molecular subtypes have been associated with prognosis and with sensitivity to chemotherapy. For instance, it has been shown that the Luminal A mRNA group has a favorable prognosis compared to the other molecular subtypes and that the Basal mRNA group has the worst prognosis [15, 18] . The same is true for the ER? IHC /HER2-IHC and the triple negative IHC subgroups. In addition, the Basal mRNA (or triple negative IHC ) and HER2? molecular and IHC groups have been shown to be relatively sensitive to CT while the Luminal molecular and IHC groups are less so [30, 31] . A possible confounder in the response evaluation of our study could be the different regimens of chemotherapy that patients received. However, Abbreviations: ERI-, endocrine non-responsive; ERI?, incompletely endocrine responsive; ERI??, highly endocrine responsive the different regimens are not restricted to or overrepresented in specific subtypes (with the exception of the trastuzumab-based treatment regimen) and since other studies that used the same regimen across all subtypes reported similar results, we consider the overall conclusions to be valid [30, 32] . For the day-to-day management of breast cancer with preoperative chemotherapy, the questions arises whether the additional effort and expense of true molecular subtyping is justified by an improved accuracy of response prediction. We examined 195 tumor biopsies from breast cancer patients who were scheduled for neoadjuvant chemotherapy, and we classified the tumors according to routine clinical tests for ER and PR protein expression as well as HER2 gene amplification. Using mRNA expression microarrays, we also classified the tumors according to the molecular subtypes that have been derived from unsupervised, hierarchical clustering of primary human breast cancers. The comparison of the two subtyping systems suggests that molecular subtyping will probably not have a major impact on treatment selection for preoperative chemotherapy for most patients with breast cancer. The Luminal and Basal molecular subtypes largely coincide with the clinical subtypes Luminal IHC (ER? IHC /HER2-IHC ) and triple negative IHC . The use of a molecular classification system does not appear to offer a better prediction of neoadjuvant therapy response than a simpler routine IHC/FISH based method. The further subdivision into Luminal A mRNA and Luminal B mRNA groups is not mirrored by the immunohistochemistry for the Progesterone receptor, nor by the differentiation between 'highly endocrine responsive' and 'incompletely endocrine responsive' tumors. In contrast to what was reported by others [33] , we did not observe a significantly better response to CT in Luminal B mRNA tumors in comparison to Luminal A mRNA tumors. It should be noted that the sample size could obscure small, but real, differences in response rates. However, the clinical relevance of these small differences is arguable. None of the three approaches to further subdivide the ER? IHC /HER2-IHC group appears to result in better predictors of chemotherapy response, despite the fact that the prognostic power of each of these has been well documented [34] [35] [36] [37] [38] [39] . Although the Luminal tumors in general do not reach a pCR, a significant proportion (53%) of these achieve a reduction in primary (breast) tumor volume of at least 50%. Treatment of these tumors with chemotherapy can allow breast-conserving surgery to take place [34] [35] [36] [37] [38] [39] and as such can be an effective treatment option for this group. The Normal-like subgroup is so small that no conclusions can be drawn at this moment.
Quite a different situation, however, exists in the group of tumors that harbor a HER2 gene amplification. The concordance between the HER2? IHC and HER2? mRNA subtypes is low. A small part of this lack of concordance can be explained by false-positive HER2 IHC staining. This is not unexpected, as several studies have investigated the reproducibility of immunohistochemistry for HER2 protein expression, and poor results with false-positive rates around 10-15% have been reported [10, 11] .
The remaining discrepancies are the result of intrinsic differences between the two subtyping methods. Many HER2-amplified tumors are classified as Luminal tumors in the molecular classification (34%). All HER2? IHC now routinely receive trastuzumab as part of the (neo)adjuvant regimen and this has proven to be very effective. In our hands, the HER2? IHC /ER-IHC tumors are particularly sensitive to the trastuzumab/paclitaxel/carboplatin (TPC) regimen and achieve a pCR rate of 64% (Supplemental Table II ). The response rate of the molecular HER2 subtype is lower (54%, Table 4 ) and does not improve on the clinical response prediction. Interestingly, however, the HER2-amplified tumors that are classified as Luminal by mRNA expression, have a very low pCR rate (8% ,  Table 4 ), which is lower than that of the clinically identifiable HER2?/ER? group (21%, Supplemental Table II) . In univariate analyses, only the Luminal molecular subtype and ER-status were found to be significant predictors of response (variables tested included: grade ([2), age ([48) , tumor size ([T2) and lymph node involvement). In a multivariate analysis (logistic regression), the model including ER-status and Luminal molecular subtype was better in predicting response than the model with ER-status alone, but not significantly so (P = 0.08; Supplemental Table III) . To perform a conclusive multivariate analysis, more samples will be needed. Thus, intrinsic resistance of HER2-amplified Luminal mRNA tumors to trastuzumab-based chemotherapy regimens may exist. Reported mechanisms of resistance to trastuzumab include altered receptor-antibody interaction, signaling by HER receptor family members, IGF1R signaling, modulation of P27 KIP1 and loss of PTEN and/or PI3K pathway activation [40, 41] . We observed that the PTEN mRNA expression in the HER2? IHC /Luminal mRNA group tended to be higher than that in the HER2? IHC /non-Luminal mRNA group (P = 0.06, Mann-Whitney test), suggesting that PTEN inactivation has no role in this context. The number of tumors in our series is small and a recent, larger study reported more similar response rates for HER2? IHC / ER? IHC and HER2? IHC /ER-IHC patients to trastuzumabbased treatment (47 vs. 61%, respectively) than what we have found (21 vs. 64%) [42] . Although a different treatment regimen was used in that study (trastuzumab with paclitaxel and FEC) and they did not include the molecular classification in their analysis, confirmation of our finding from independent series is required. If confirmed, this finding could lead to an mRNA expression-based test on pretreatment biopsies predictive for tumor unresponsiveness to trastuzumab-based treatment. The efficacy of newer drugs that block the HER2 receptor by other mechanisms than trastuzumab, such as lapatinib, should be explored with priority in these relatively insensitive subgroups.
We conclude that the time has not yet come for the routine use of molecular subtyping in the neoadjuvant treatment setting of breast cancer. In our series of 195 patients, standard subtyping based on ER and PR status and HER2 gene amplification performed as well and remains essential for treatment selection. In the HER2? IHC 
